{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:24:04Z","timestamp":1787664244386,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["2024-A-05"],"award-info":[{"award-number":["2024-A-05"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["25lk0221211h0001"],"award-info":[{"award-number":["25lk0221211h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10147-026-03087-y","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:25:50Z","timestamp":1781004350000},"page":"1852-1857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A multicenter survey on BRAF screening for the implementation of perioperative cancer genomic medicine for resectable colorectal oligometastases"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-8452","authenticated-orcid":false,"given":"Shin","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Matsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Shiomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Takamizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiharu","family":"Hiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Kakisaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Ohnuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Kotaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"3087_CR1","unstructured":"Network NCC (2025) NCCN Guidelines Version 4.2025 Breast Cancer 2025 [Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf]."},{"key":"3087_CR2","unstructured":"Network NCC(2025) NCCN Guidelines Version 3.2025 Gastric Cancer 2025 [Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf]."},{"key":"3087_CR3","unstructured":"Network NCC(2025) NCCN Guidelines Version 8.2025 Non-Small Cell Lung Cancer 2025 [Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf]."},{"key":"3087_CR4","unstructured":"Network NCC (2025) NCCN Guidelines Version 2.2025 Melanoma: Cutaneous 2025 [Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf]."},{"issue":"3","key":"3087_CR5","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s10120-024-01467-9","volume":"27","author":"M Tokunaga","year":"2024","unstructured":"Tokunaga M, Machida N, Mizusawa J et al (2024) Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1\/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Gastric Cancer 27(3):580\u2013589","journal-title":"Gastric Cancer"},{"issue":"32","key":"3087_CR6","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.22.00380","volume":"40","author":"RD Hofheinz","year":"2022","unstructured":"Hofheinz RD, Merx K, Haag GM et al (2022) FLOT\/Trastuzumab\/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2\u2013positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group. J Clin Oncol 40(32):3750\u20133761","journal-title":"J Clin Oncol"},{"key":"3087_CR7","doi-asserted-by":"crossref","unstructured":"Wagner AD, Grabsch HI, Mauer M, et al (2023) Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): first results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group. J Clin Oncol 41(16_suppl):4057.","DOI":"10.1200\/JCO.2023.41.16_suppl.4057"},{"issue":"11","key":"3087_CR8","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jtho.2023.07.006","volume":"18","author":"JM Lee","year":"2023","unstructured":"Lee JM, McNamee CJ, Toloza E et al (2023) Neoadjuvant targeted therapy in resectable NSCLC: current and future perspectives. J Thorac Oncol 18(11):1458\u20131477","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3087_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/107327481402100307","volume":"21","author":"RD Hall","year":"2014","unstructured":"Hall RD, Kudchadkar RR (2014) BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. Cancer Control 21(3):221\u2013230","journal-title":"Cancer Control"},{"issue":"17","key":"3087_CR10","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 381(17):1632\u20131643","journal-title":"N Engl J Med"},{"issue":"3","key":"3087_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","volume":"31","author":"S Kopetz","year":"2025","unstructured":"Kopetz S, Yoshino T, Van Cutsem E et al (2025) Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med 31(3):901\u2013908","journal-title":"Nat Med"},{"issue":"7","key":"3087_CR12","doi-asserted-by":"publisher","first-page":"e180996","DOI":"10.1001\/jamasurg.2018.0996","volume":"153","author":"GA Margonis","year":"2018","unstructured":"Margonis GA, Buettner S, Andreatos N et al (2018) Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg 153(7):e180996","journal-title":"JAMA Surg"},{"issue":"9","key":"3087_CR13","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1245\/s10434-020-08817-8","volume":"27","author":"S Kobayashi","year":"2020","unstructured":"Kobayashi S, Takahashi S, Takahashi N et al (2020) Survival outcomes of resected BRAF V600E mutant colorectal liver metastases: a multicenter retrospective cohort study in Japan. Ann Surg Oncol 27(9):3307\u20133315","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"3087_CR14","doi-asserted-by":"publisher","first-page":"6998","DOI":"10.1002\/cam4.4227","volume":"10","author":"S Kobayashi","year":"2021","unstructured":"Kobayashi S, Takahashi S, Nomura S et al (2021) BRAF V600E potentially determines \u201cOncological Resectability\u201d for \u201cTechnically Resectable\u201d colorectal liver metastases. Cancer Med 10(20):6998\u20137011","journal-title":"Cancer Med"},{"issue":"1","key":"3087_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1186\/s12885-023-11311-5","volume":"23","author":"S Kobayashi","year":"2023","unstructured":"Kobayashi S, Bando H, Taketomi A et al (2023) NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases. BMC Cancer 23(1):779","journal-title":"BMC Cancer"},{"key":"3087_CR16","doi-asserted-by":"publisher","first-page":"S428","DOI":"10.1016\/j.annonc.2023.09.1782","volume":"34","author":"S Kobayashi","year":"2023","unstructured":"Kobayashi S, Takamoto T, Shiomi A et al (2023) 591P survival and benefit of adjuvant chemotherapy (ACT) by circulating tumor DNA (ctDNA)-based genomic profile and molecular residual disease (MRD) in resectable colorectal oligometastases (CRM): PRECISION, a prospective multicenter study. Ann Oncol 34:S428\u2013S429","journal-title":"Ann Oncol"},{"issue":"3","key":"3087_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"3087_CR18","doi-asserted-by":"crossref","unstructured":"Schroen AT, Petroni GR, Hongkun Wang N, et al. (2010) Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. ClinI Trials 7(4):312\u201321.","DOI":"10.1177\/1740774510374973"},{"issue":"1","key":"3087_CR19","doi-asserted-by":"publisher","first-page":"e2250996","DOI":"10.1001\/jamanetworkopen.2022.50996","volume":"6","author":"C Shadbolt","year":"2023","unstructured":"Shadbolt C, Naufal E, Bunzli S et al (2023) Analysis of rates of completion, delays, and participant recruitment in randomized clinical trials in surgery. JAMA Netw Open 6(1):e2250996","journal-title":"JAMA Netw Open"},{"issue":"22","key":"3087_CR20","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1158\/1078-0432.CCR-16-0338","volume":"22","author":"HA Massett","year":"2016","unstructured":"Massett HA, Mishkin G, Rubinstein L et al (2016) Challenges facing early phase trials sponsored by the National Cancer Institute: an analysis of corrective action plans to improve accrual. Clin Cancer Res 22(22):5408\u20135416","journal-title":"Clin Cancer Res"},{"key":"3087_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cct.2015.07.010","volume":"45","author":"DF Heitjan","year":"2015","unstructured":"Heitjan DF, Ge Z, Ying GS (2015) Real-time prediction of clinical trial enrollment and event counts: a review. Contemp Clin Trials 45:26\u201333","journal-title":"Contemp Clin Trials"},{"issue":"13","key":"3087_CR22","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMsb1607705","volume":"375","author":"IF Tannock","year":"2016","unstructured":"Tannock IF, Hickman JA (2016) Limits to personalized cancer medicine. N Engl J Med 375(13):1289\u20131294","journal-title":"N Engl J Med"},{"issue":"1","key":"3087_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","volume":"14","author":"E Fountzilas","year":"2022","unstructured":"Fountzilas E, Tsimberidou AM, Vo HH et al (2022) Clinical trial design in the era of precision medicine. Genome Med 14(1):101","journal-title":"Genome Med"},{"issue":"Suppl 1","key":"3087_CR24","first-page":"9","volume":"14","author":"DC Moore","year":"2023","unstructured":"Moore DC, Guinigundo AS (2023) Biomarker-driven oncology clinical trials: novel designs in the era of precision medicine. J Adv Pract Oncol 14(Suppl 1):9\u201313","journal-title":"J Adv Pract Oncol"},{"issue":"3","key":"3087_CR25","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.surg.2023.08.043","volume":"175","author":"V Wu","year":"2024","unstructured":"Wu V, Chichura AM, Dickard J et al (2024) Perioperative genetic testing and time to surgery in patients with breast cancer. Surgery 175(3):712\u2013717","journal-title":"Surgery"},{"issue":"1","key":"3087_CR26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s13187-013-0548-z","volume":"29","author":"JR Gregg","year":"2014","unstructured":"Gregg JR, Horn L, Davidson MA et al (2014) Patient enrollment onto clinical trials: the role of physician knowledge. J Cancer Educ 29(1):74\u201379","journal-title":"J Cancer Educ"},{"issue":"6","key":"3087_CR27","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1200\/JOP.2013.001120","volume":"9","author":"CP Somkin","year":"2013","unstructured":"Somkin CP, Ackerson L, Husson G et al (2013) Effect of medical oncologists\u2019 attitudes on accrual to clinical trials in a community setting. J Oncol Pract 9(6):e275\u2013e283","journal-title":"J Oncol Pract"},{"issue":"5","key":"3087_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/1740774514536000","volume":"11","author":"SR Jacobs","year":"2014","unstructured":"Jacobs SR, Weiner BJ, Reeve BB et al (2014) Organizational and physician factors associated with patient enrollment in cancer clinical trials. Clin Trials 11(5):565\u2013575","journal-title":"Clin Trials"},{"issue":"1","key":"3087_CR29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12029-025-01315-8","volume":"56","author":"T Mori","year":"2025","unstructured":"Mori T, Kobayashi S, Tsukada Y et al (2025) Survival outcomes of patients with BRAF V600E-mutant resectable extrahepatic colorectal oligometastases after upfront metastasectomy. J Gastrointest Cancer 56(1):192","journal-title":"J Gastrointest Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03087-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03087-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03087-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:08:45Z","timestamp":1787663325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03087-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3087"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03087-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shin Kobayashi declares honoraria from Ono Pharmaceutical, Merck Biopharma, and Guardant Health. Nobuhisa Matsuhashi declares honoraria from Abbott, Alfresa Pharma Corp, AMCO Inc., Astellas Pharma Inc., AstraZeneca, Bayer Yakuhin, Bristol-Myers Squibb, Chugai Pharm., Covidien Japan, Daiichi Sankyo, EA Pharma, Eisai, Eli Lilly Japan, Guardant Health Japan Corp., Intuitive Surgical, Johnson & Johnson, Kaken Pharm., Kyowa Kirin, MC Medical, Merck Biopharma Japan, Miyarisan Pharm., MSD, Novartis, Olympus Marketing, Inc., Ono Pharm., Taiho Pharm., TAKATA Pharm., Takeda Pharm., TERUMO, Tsumura, Viatris, Yakult Honsha, and Zeria Pharmaceutical Co., Ltd., grant paid to his institution from Covidien Japan, JMS, Johnson & Johnson, Kaken Pharm., Nippon Kayaku, Taiho Pharm., TERUMO, and Toray Medical, and research funding paid to his institution from e-NA Biotec Inc., EPS Corporation, and Ono Pharmaceutical. Hideaki Bando has received research funding from GlaxoSmithKline and honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, and Guardant Health. Takayuki Yoshino has received honoraria from Chugai Pharmaceutical, Takeda Pharmaceutical, Merck Biopharma, Ono Pharmaceutical, and MSD K.K.; consulting fee from Sumitomo Corp, and Indivumed; and research funding from Amgen, Bristol-Myers Squibb, Caris MPI, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Exact Sciences, FALCO Biosystems, Medical & Biological Laboratories, Merus N.V., Miyarisan Pharmaceutical, Molecular Health GmbH, MSD, Natera Inc., Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer Japan, Roche Diagnostics, Sanofi, Sysmex, Taiho Pharmaceutical, and Takeda Pharmaceutical.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}